Nobligan Retard (Tramadol Hydrochloride)

Nobligan Retard, an opioid analgesic, is used to manage pain conditions that require strong central analgesia.

• Acute pain: provides effective relief for moderate to severe pain episodes such as injury or trauma.
• Post‑operative pain: helps control pain following surgical procedures when other analgesics are insufficient.
• Chronic pain: used when long‑term pain persists and alternative non‑opioid treatments have not achieved adequate control.

• Tramadol Hydrochloride acts as a centrally acting mu‑opioid receptor agonist while also inhibiting the reuptake of norepinephrine and serotonin. This dual mechanism reduces the perception of pain in the central nervous system and modulates descending inhibitory pathways, resulting in analgesia without the full opioid receptor activation seen with stronger opioids.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Dizziness: sensation of light‑headedness or unsteadiness.
• Constipation: reduced bowel motility leading to hard stools.
• Somnolence: increased sleepiness or fatigue.
• Headache: mild to moderate cranial pain.
• Dry mouth: reduced salivation causing oral discomfort.

Serious or Rare Side Effects

• Seizures: risk increases with high doses or interacting medications.
• Serotonin syndrome: potentially life‑threatening when combined with serotonergic agents.
• Respiratory depression: reduced breathing effort, especially in compromised patients.
• Anaphylaxis: severe allergic reaction with rash, swelling, and airway compromise.
• Severe hypotension: sudden drop in blood pressure causing dizziness or fainting.
• Dependence or addiction: potential for misuse with prolonged use.

Before prescribing Nobligan Retard, clinicians should evaluate patient‑specific risk factors and monitor for adverse outcomes.

• Renal or hepatic impairment: adjust dose or avoid if function is severely reduced.
• Respiratory depression: avoid in patients with existing respiratory compromise.
• Concomitant CNS depressants: use caution when combined with alcohol, benzodiazepines, or other sedatives.
• History of seizures: assess risk and consider alternative therapy.
• Potential for dependence: limit duration and monitor for signs of misuse.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Tramadol may interact with several drug classes, requiring careful assessment.

Major Interactions (Avoid)

• MAO inhibitors: risk of hypertensive crisis and serotonin syndrome.
• SSRIs, SNRIs, or other serotonergic agents: increased risk of serotonin syndrome.
• CNS depressants (e.g., benzodiazepines, alcohol): additive sedation and respiratory depression.
• CYP2D6 inhibitors (e.g., quinidine, fluoxetine): may raise tramadol plasma levels.
• Other opioids: heightened risk of respiratory depression and overdose.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce analgesic effect.
• Antihistamines: can enhance sedation.
• Diuretics: may increase risk of hypotension.
• Antihypertensives: possible additive blood‑pressure lowering effect.
• NSAIDs: combined use may raise gastrointestinal bleeding risk.